MicroRNA-Based Cancer Mortality Risk Scoring System and hTERT Expression in Early-Stage Oral Squamous Cell Carcinoma

Angela J. Yoon; Regina M. Santella; Shuang Wang; David I. Kutler; Richard D. Carvajal; Elizabeth Philipone; Tian Wang; Scott M. Peters; Claire R. Stewart; Fatemeh Momen-Heravi; Scott Troob; Matt Levin; Zohreh AkhavanAghdam; Austin J. Shackelford; Carleigh R. Canterbury; Masataka Shimonosono; Brenda Y. Hernandez; Bradley D. McDowell; Hiroshi Nakagawa

doi:10.1155/2021/8292453

Back

MicroRNA-Based Cancer Mortality Risk Scoring System and hTERT Expression in Early-Stage Oral Squamous Cell Carcinoma

Journal article

Open access

Peer reviewed

MicroRNA-Based Cancer Mortality Risk Scoring System and hTERT Expression in Early-Stage Oral Squamous Cell Carcinoma

Angela J. Yoon, Regina M. Santella, Shuang Wang, David I. Kutler, Richard D. Carvajal, Elizabeth Philipone, Tian Wang, Scott M. Peters, Claire R. Stewart, Fatemeh Momen-Heravi, …

Journal of oncology, Vol.2021, 8292453

01/15/2021

DOI: 10.1155/2021/8292453

PMCID: PMC7822680

PMID: 33510789

Files and links (1)

url

https://doi.org/10.1155/2021/8292453View

Published (Version of record) Open Access

Abstract

We have previously constructed a novel microRNA (miRNA)-based prognostic model and cancer-specific mortality risk score formula to predict survival outcome in oral squamous cell carcinoma (OSCC) patients who are already categorized into "early-stage" by the TNM staging system. A total of 836 early-stage OSCC patients were assigned the mortality risk scores. We evaluated the efficacy of various treatment regimens in terms of survival benefit compared to surgery only in patients stratified into high (risk score >= 0) versus low (risk score <0) mortality risk categories. For the high-risk group, surgery with neck dissection significantly improved the 5-year survival to 75% from 46% with surgery only (p<0.001); a Cox proportional hazard model on time-to-death demonstrated a hazard ratio of 0.37 for surgery with neck dissection (95% CI: 0.2-0.6; p=0.0005). For the low-risk group, surgery only was the treatment of choice associated with 5-year survival benefit. Regardless of treatment selected, those with risk score >= 2 may benefit from additional therapy to prevent cancer relapse. We also identified hTERT (human telomerase reverse transcriptase) as a gene target common to the prognostic miRNAs. There was 22-fold increase in the hTERT expression level in patients with risk score >= 2 compared to healthy controls (p<0.0005). Overexpression of hTERT was also observed in the patient-derived OSCC organoid compared to that of normal organoid. The DNA cancer vaccine that targets hTERT-expressing cells currently undergoing rigorous clinical evaluation for other tumors can be repurposed to prevent cancer recurrence in these high-risk early-stage oral cancer patients.

Oncology

Life Sciences & Biomedicine

Science & Technology

Details

Title: Subtitle: MicroRNA-Based Cancer Mortality Risk Scoring System and hTERT Expression in Early-Stage Oral Squamous Cell Carcinoma
Creators: Angela J. Yoon - Columbia University Irving Medical Center
Regina M. Santella - Columbia University
Shuang Wang - Columbia University
David I. Kutler - Weill Cornell Medicine
Richard D. Carvajal - Columbia University Irving Medical Center
Elizabeth Philipone - Columbia University Irving Medical Center
Tian Wang - Columbia University
Scott M. Peters - Columbia University
Claire R. Stewart - Weill Cornell Medicine
Fatemeh Momen-Heravi - Columbia University Irving Medical Center
Scott Troob - Columbia University Irving Medical Center
Matt Levin - Cell IDx (United States)
Zohreh AkhavanAghdam - Cell IDx (United States)
Austin J. Shackelford - Columbia University Irving Medical Center
Carleigh R. Canterbury - Columbia University Irving Medical Center
Masataka Shimonosono - Columbia University Irving Medical Center
Brenda Y. Hernandez - University of Hawaii System
Bradley D. McDowell - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA
Hiroshi Nakagawa - Columbia University Irving Medical Center
Resource Type: Journal article
Publication Details: Journal of oncology, Vol.2021, 8292453
DOI: 10.1155/2021/8292453
PMID: 33510789
PMCID: PMC7822680
NLM abbreviation: J Oncol
ISSN: 1687-8450
eISSN: 1687-8450
Publisher: Hindawi Publishing Group
Number of pages: 11
Grant note: P30ES009089 / NIH/NIEHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS) Translational Research Program at WCMC Pathology and Laboratory Medicine R01DE026801 / NIH/NIDCR; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR) P30CA013696; P01CA098101; U54CA163004; P30CA086862; P30CA071789 / NIH/NCI; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) R01AA026297 / NIH/NIAAA; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)
Language: English
Date published: 01/15/2021
Academic Unit: Holden Comprehensive Cancer Center
Record Identifier: 9984368075402771

Metrics

10 Record Views

1 Times Cited - Web of Science